Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14713200 | 0.91 | KMT2A (0.38) | KDM4EALDH1A1SMN1; SMN2TBXAS1 | |
| SCHEMBL4213888 | 0.89 | KDM4E (0.43) | ALOX5KDM4EPTPN11FNTAFNTB | |
| SCHEMBL2085387 | 0.89 | KDM4E (0.43) | ALOX5KDM4EPTPN11FNTAFNTB | |
| SCHEMBL2085390 | 0.89 | KDM4E (0.43) | ALOX5KDM4EPTPN11FNTAFNTB | |
| SCHEMBL4213890 | 0.88 | KDM4E (0.40) | ALOX5KDM4EPTPN11FNTAFNTB | |
| SCHEMBL4213886 | 0.88 | KDM4E (0.40) | ALOX5KDM4EPTPN11FNTAFNTB | |
| SCHEMBL4210691 | 0.86 | KDM4E (0.39) | ALOX5KDM4EPTPN11FNTAFNTB | |
| SCHEMBL4210700 | 0.86 | KDM4E (0.39) | ALOX5KDM4EPTPN11FNTAFNTB | |
| SCHEMBL4217552 | 0.86 | HTR7 (0.42) | ALOX5KDM4EPTPN11PTGESPPARG | |
| SCHEMBL2086117 | 0.84 | AKR1C3 (0.51) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | US | disclosed |
| EP-1943213-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | Galderma Research & Development (FR) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007049158-A2 | PPAR MODULATING BIAROMATIC COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | PPARG, PPARD, PPARA | ALOX5 713/4885KDM4E 2728/4885PTPN11 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.